Papers

Luoma et al. Tissue-resident memory and circulating T cells are early responders to pre-surgical cancer immunotherapy. Cell (2022) Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors.

Kula et al. T-Scan: A Genome-wide Method for the Systematic Discovery of T Cell Epitopes. Cell (2019) Pioneering work on the TargetScan discovery platform.

Ferretti et al. Unbiased Screens Show CD8+ T Cells of COVID-19 Patients Recognize Shared Epitopes in SARS-CoV-2 that Largely Reside outside the Spike Protein. Immunity (2020) TargetScan platform used to identify SARS-CoV-2 targets of T cells in recovering COVID-19 patients.

Posters

Padmanabhan, et al. Development of a target agnostic platform to assess the reactivity of T cell receptor (TCR)-engineered T cell (TCR-T) therapies to primary human tissues. SITC 2024

Bowman, et al. Preclinical Models for T-Plex, a Customized Multiplexed TCR-T Cell Therapy Addressing Intra-Tumor Antigen and HLA Heterogeneity. SITC 2024

Kulkarni, et al. Discovery of a MAGE-A4-specific TCR-T therapy candidate for multiplex treatment of solid tumors. SITC 2024

Thomas et al. Initial Data From a Phase 1, First In Human Clinical Trial For T-Plex, A Multiplexed, Enhanced T Cell Receptor-Engineered T Cell(TCR-T) Therapy For Solid Tumors. 2024 ASCO

Al Malki et al. Phase 1 Trial of TSC-100 and TSC-101, Engineered T-Cell Therapies Targeting Minor Histocompatibility Antigens to Eliminate Residual Disease after Hematopoietic Cell Transplantation. 2024 ASCO

Bader et al. Non-Clinical Development of T-Plex Component TSC-201-B0702: a TCR-T Cell Therapy Directed to a Novel HLA-B*07:02-Restricted MAGE-C2 Epitope for the Treatment of Solid Tumors. 2024 ASGCT

Khokhar et al. Nonclinical development of T-Plex component TSC-204-A0101: a natural TCR-T cell therapy for the treatment of MAGE-A1- and HLA-A*01:01-positive cancers. 2024 ASGCT

Moser et al. Trial in progress: A phase 1, first-in-human clinical trial for T-Plex, a multiplex, enhanced T cell receptor-engineered T cell (TCR-T) therapy for solid tumors. 2024 ASGCT

Al Malki et al. Trial in progress: A phase 1 trial of TSC-100 and TSC-101, engineered TCR-T cell therapies that target minor histocompatibility antigens to eliminate residual AML, ALL or MDS after hematopoietic cell transplantation. 2024 ASGCT

Moser et al. Trial in progress: A phase 1, first-in-human clinical trial for T-Plex, a multiplex, enhanced T cell receptor-engineered T cell therapy (TCR-T) for solid tumors. AACR 2024

Al Malki et al. Trial in progress: A phase 1 trial of TSC-100 and TSC-101, engineered T cell therapies that target minor histocompatibility antigens to eliminate residual disease after hematopoietic cell transplantation. AACR 2024

Al Malki et al. Initial Results of a Phase 1 trial of TSC-100 and TSC-101, Engineered T Cell Therapies that Target Minor Histocompatibility Antigens to Prevent Relapse after Allogeneic Hematopoietic Cell Transplantation. ASH 2023

Ferretti et al. Discovery of novel MAGEC2 epitopes for TCR-T adoptive cell therapy from expanded T cell clones of TIL therapy products. SITC 2023

Tadros et al. Discovery of MAGE-A1-specific TCR-T cell therapy candidates to expand multiplex therapy of solid tumors. SITC 2023

Nayar et al. Overcoming tumor heterogeneity – Clinical trial assays to prospectively assign patients customized multiplexed TCR-T cell therapy in Phase 1. SITC 2023

Al Malki et al. Phase 1 trial of TSC-100 and TSC-101, Engineered T-Cell Therapies Targeting Minor Histocompatibility Antigens to Eliminate Residual Disease after Hematopoietic Cell Transplantation. SITC 2023

Chattopadhyay et al. Product Characteristics and Clinical Trial Design for T-Plex, a Multiplexed, Enhanced T cell Receptor-Engineered T cell Therapy for Solid Tumors. SITC 2023

Chattopadhyay et al. Product characteristics and clinical trial design for T-Plex: Multiplexed, enhanced T cell receptor-engineered T cell therapy for solid tumors. ASCO 2023

Al Malki et al. A Phase 1 Trial of TSC-100 and TSC-101, Engineered T Cell Therapies That Target Minor Histocompatibility Antigens to Eliminate Residual Disease After Hematopoietic Cell Transplantation. ASGCT 2023

Reshef et al. Trial in Progress: A Phase 1 Umbrella Study of TCR-Engineered T Cells That Target HA-1 (TSC-100) and HA-2 (TSC-101) to Treat Residual Leukemia after Hematopoietic Cell Transplantation. ASH 2022

Jurewicz et al. Discovery of PRAME-specific TCR-T cell therapy candidates for the treatment of solid tumors. SITC 2022

Boudot et al. Multiplexed TCR-T Cell Therapy Targeting MAGE-A1 and PRAME Enhances The Activity of Adoptive T Cell Therapy in Pre-Clinical Models. SITC 2022

Jangalwe et al. Discovery of TSC-200-A02: A Natural HPV16 E7-specific TCR-T Cell Therapy Candidate for the Treatment of HPV-positive Solid tumors. ASGCT 2022

Wang et al. Multiplexed TCR-T Therapy: A Strategy to Enhance the Efficacy of Engineered Adoptive Cell Therapy. ASGCT 2022

Chattopadhyay et al. Product Characteristics and Multi-Arm Clinical Trial Design for TSC-100 and TSC-101, TCR-T Cells That Target Leukemia Following Hematopoietic Cell Transplantation. ASH 2021

Nayar R. et al. Discovery of TSC-101: A First in Class Natural HA-2 Specific TCR to Treat Leukemia Following Hematopoietic Stem Cell Transplant Therapy. ASH 2021

Wang et al. Comprehensive Identification of Tumor-reactive TCRs and Cognate Targets for Novel TCR T-cell Cancer Therapies. ASGCT (2020)

Ferretti et al. Unbiased Genome-wide Discovery Using TScan Reveals Shared Immunodominant CD8+ T Cell Epitopes in SARS-CoV-2. ASGCT (2020)

Nayar et al. Discovery of TSC-100: A Natural HA-1-specific TCR to Treat Leukemia Following Hematopoietic Stem Cell Transplant Therapy. SITC (2020)

Presentations

Company Presentation – November 2024

MacBeath, Discovery of immunodominant T cell targets in COVID-19 patients and design of novel T cell-based vaccines, Cell-Mediated Therapies for Infectious Disease Summit (2021)